Home
Team
Technology
Investors
Pipeline
Contact Us

HBP Press Release – Dose First US patient

Home
HBP Press Release – Dose First US patient

23/04/201521/10/2023
admin
0 Comments
FY2015

Post navigation

Previous: HBP Press Release – Initiates Enrollment for Twelvth Cohort in Polish Phase I,II Clinical Study

HBP Press Release Closes Additional Private Placement Financing:Next

Search for:

Recent Posts

Helix Biopharma Corp. Announces Appointment of New Chief Financial Officer
Helix Biopharma Corp. Reports Voting Results
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL 2023 YEAR-END RESULTS
Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (poster)

Recent Stories

Helix Biopharma Corp. Announces Appointment of New Chief Financial Officer Feb 13, 2024
Helix Biopharma Corp. Reports Voting Results Jan 18, 2024
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL 2023 YEAR-END RESULTS Oct 27, 2023
Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 13, 2023
2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (poster) Oct 13, 2023

Quick Links

Team
Technology
Pipeline
News
Investors
Contact Us

Other Links

Privacy Policy
Cookie Policy
Sedar Filings
ClinicalTrials.gov

Get In Touch

Bay Adelaide Centre - North Tower 40 Temperance Street, Suite 2700 Toronto, ON M5H 0B4
helix@helixbiopharma.com
+1 604 684 2181
Mon-Fri: 9.00am To 5.00pm

Copyright © 2023 All Rights Reserved | Helix biopharma